Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Outperform Rating and Raises Price Target for Cannae Holdings

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Finance analyst
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Analyst Ian Zaffino of Oppenheimer continues to show confidence in Cannae Holdings (NYSE: CNNE) by maintaining an Outperform rating and raising the price target to $27. This positive stance reflects belief in the company’s performance and growth potential. The increased price target signals optimism for Cannae Holdings’ future in the market, highlighting its promising outlook.

CNNE Stock Analysis: Strong Performance and Positive Price Momentum on March 6, 2024

On March 6, 2024, CNNE stock showed strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been on an upward trend in the long term.

CNNE shares saw a price increase of $0.12 since the market last closed, representing a 0.55% rise. The stock opened at $21.97, which was $0.22 higher than its previous close. This opening price suggests that there was positive momentum for CNNE at the start of the trading day.

Investors may be interested in CNNE stock due to its strong performance and positive price momentum. Trading near the top of its 52-week range indicates that the stock has been performing well compared to its past performance. Additionally, being above its 200-day simple moving average suggests that the stock is in an uptrend over the long term.

It is important for investors to conduct thorough research and analysis before making any investment decisions. While past performance can provide some insights into future potential, it is also essential to consider other factors such as company financials, industry trends, and market conditions.

Overall, CNNE stock showed promising performance on March 6, 2024, with a price increase and strong momentum. Investors may want to keep an eye on this stock for potential investment opportunities.

CNNE Stock Analysis: Revenue Decline, Net Income Increase, and EPS Improvement

On March 6, 2024, CNNE stock experienced mixed performance based on the latest financial data provided by CNN Money. The company’s total revenue for the past year was $570.00 million, which decreased by 13.91% compared to the previous year. However, the total revenue remained flat since the last quarter at $119.30 million.

Despite the decline in total revenue, CNNE managed to increase its net income over the past year. The company reported a net income of -$307.00 million for the year, which represented a 28.29% increase compared to the previous year. In the last quarter, CNNE’s net income improved even further, reaching -$58.40 million, a significant 62.87% increase from the previous quarter.

Earnings per share (EPS) also showed improvement for CNNE. The company reported an EPS of -$4.18 for the past year, which was a 20.28% increase compared to the previous year. In the last quarter, the EPS remained steady at -$0.83, showing no change from the previous quarter.

Overall, CNNE stock performance on March 6, 2024, reflected a mixed picture. While the company experienced a decline in total revenue, it managed to increase its net income and EPS over the past year. Investors may want to closely monitor CNNE’s financial performance in the coming quarters to assess the company’s growth prospects and potential for stock price appreciation.

Tags: CNNE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Cyber-security-technology

Consistent Perform Ratings for ChargePoint Holdings Inc despite Recent Developments

Applied Therapeutics Reports Disappointing Q4 Financial Results

Automotive Trading online

Challenges and Concerns for Nio Analysts Slash Price Targets

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com